FrancisWilliamPriceJr.MD

Ophthalmology • Indianapolis, IN

Cataract Related, Cornea & External Disease, Glaucoma Related

Medical Director at Price Vision Group

Join to view full profile

Dr. Price is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Price's full profile

Already have an account?

Office
9002 N Meridian St
# SUITE100
Indianapolis, IN 46260
Phone+1 317-844-5530

Fax+1 317-844-5590

Education & Training

Indiana University School of MedicineResidency, Ophthalmology, 1978 - 1981
Indiana University School of Medicine/Methodist HospitalInternship, Transitional Year, 1977 - 1978
Indiana University School of MedicineClass of 1977

Certifications & Licensure

HI State Medical License 1986 - 2026
IN State Medical License 1977 - 2025
FL State Medical License 1973 - 1998
LA State Medical License 1981 - 1982
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Study of Endothelial Keratoplasty Outcomes Start of enrollment: 2008 Feb 01
Completed
Not Applicable
Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients Start of enrollment: 2009 May 01
Terminated
Not Applicable
Cross Linking for Treatment of Corneal Infection Start of enrollment: 2009 May 01
Terminated
Not Applicable
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia Start of enrollment: 2010 May 01
Completed
Phase 2
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus Start of enrollment: 2012 Jul 01
Completed
Phase 3
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty Start of enrollment: 2013 Mar 01
Completed
Phase 4
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects Start of enrollment: 2013 Oct 01
Recruiting
Not Applicable
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation Start of enrollment: 2014 May 01
Completed
Phase 3
Study of Ataluren in Participants With Nonsense Mutation Aniridia Start of enrollment: 2016 Jan 31
Completed
Phase 2
Effect of TrueTear Corneal Surface Imaging Start of enrollment: 2018 Aug 13
Completed
Not Applicable
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration Start of enrollment: 2019 Jul 22
Terminated
Phase 2, Phase 3
Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections. Start of enrollment: 2019 Jul 03
Withdrawn
Phase 2, Phase 3
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy Start of enrollment: 2019 Aug 05
Completed
Phase 2, Phase 3
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Start of enrollment: 2022 Mar 14
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Enhanced Migration of Fuchs Corneal Endothelial Cells by Rho Kinase Inhibition: A Novel Ex Vivo Descemet's Stripping Only Model.
Mohit Parekh, Annie Miall, Ashley Chou, Lara Buhl, Neha Deshpande
Cells. 2024-07-19
2 citations
Initial results of DMEK combined with cataract surgery and implantation of the light-adjustable lens.
David A Price, Kathleen N Dudasko, Taylor A Hall, Marianne O Price, Francis W Price
Journal of Cataract and Refractive Surgery. 2024-03-01
The Role of Antifungal Prophylaxis After Receipt of a Positive Donor Rim Fungal Culture: The Case for Not Routinely Treating Prophylactically.
Francis W. Price
Cornea. 2021-09-01

Journal Articles

Association of the Gutta-Induced Microenvironment with Corneal Endothelial Cell Behavior and Demise in Fuchs Endothelial Corneal Dystrophy
Francis W Price, Ula V Jurkunas, JAMA

Press Mentions

Price Vision Group Participating in Clinical Study of Investigational Growth Factor Treatment for Eye Disorder, Fuchs Endothelial Corneal DystrophyMarch 10th, 2021